Quince Therapeutics, Inc.

Quince Therapeutics, Inc. is a biotechnology company focused on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. Its lead asset is eDSP, in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. The company's AIDE technology platform is a drug/device combination that uses an automated process to encapsulate a drug into a patient's own red blood cells, and includes the RCL, a sterile single-use consumable treatment kit comprising medical devices, a syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. It was incorporated in 2012 and is headquartered in South San Francisco, California.